TG Therapeutics Inc header image

TG Therapeutics Inc

TGTX

Equity

ISIN null / Valor 18511671

NASDAQ (2026-10-30)
USD 61.18+5.34%

TG Therapeutics Inc
UMushroom community rating:

star star star star star
5.00 1 votes No rating yet
NegativeNeutralPositive

About company

TG Therapeutics Inc is a biopharmaceutical company listed on the NASDAQ under the ticker symbol TGTX. The company focuses on developing innovative therapies for various diseases, with a particular emphasis on autoimmune and oncology conditions. One of its key products is BRIUMVI ® (ublituximab-xiiy), which is currently undergoing Phase 3 trials for the treatment of relapsing forms of multiple sclerosis (RMS). Through its research and development efforts, TG Therapeutics Inc aims to bring novel treatment options to patients in need.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

79.8%1Y
728%3Y
96.0%5Y

Performance

44.9%1Y
59.9%3Y
88.7%5Y

Volatility

Market cap

9365 M

Market cap (USD)

Daily traded volume (Shares)

2,856,055

Daily traded volume (Shares)

1 day high/low

32.3 / 31.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

5.00

1 votes
Performance:
starstarstarstarstar
5.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
5.00
Luba Schoenig
Switzerland, 14 Jan 2025
star star star star star
On January 14, 2025, TG Therapeutics announced preliminary net revenue results for the fourth quarter and full year of 2024, along with anticipated development milestones for 2025. The company revised its guidance upward, driven by stronger-than-expected sales of its multiple sclerosis drug, Briumvi

EQUITIES OF THE SAME SECTOR

Netscout Systems Inc
Netscout Systems Inc Netscout Systems Inc Valor: 847783
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.49%USD 38.37
Extreme Networks Inc
Extreme Networks Inc Extreme Networks Inc Valor: 653096
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.15%USD 22.61
Progress Software Corp
Progress Software Corp Progress Software Corp Valor: 963966
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%USD 45.13
Embracer Group AB
Embracer Group AB Embracer Group AB Valor: 113946352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.49%SEK 95.08
Sinch AB
Sinch AB Sinch AB Valor: 112110749
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.91%SEK 43.42
HBL Engineering Limited
HBL Engineering Limited HBL Engineering Limited Valor: 10702379
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.92%INR 799.60
Mycronic AB
Mycronic AB Mycronic AB Valor: 659217
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.65%SEK 301.00
HMS Networks AB
HMS Networks AB HMS Networks AB Valor: 36954778
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.97%SEK 487.80
Systemair AB
Systemair AB Systemair AB Valor: 113483603
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.47%SEK 85.00
Vitec Software Group AB
Vitec Software Group AB Vitec Software Group AB Valor: 30840841
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.98%SEK 308.60